Full Text View
Tabular View
No Study Results Posted
Related Studies
Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC)
This study has been terminated.
( See termination reason in detailed description )
Study NCT01009593   Information provided by Abbott

First Received on October 14, 2009.   Last Updated on September 7, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Hepatocellular Carcinoma Recurrent
Carcinoma, Hepatocellular
Liver Diseases
Neoplasms by Histologic Type
Digestive System Neoplasms
Carcinoma
Liver Neoplasms
Neoplasms
Neoplasms by Site
Digestive System Diseases
Adenocarcinoma
Neoplasms, Glandular and Epithelial
Additional conditions recognized in this trial
Adenocarcinoma, Mucinous
Gastrointestinal Diseases
Gastrointestinal Neoplasms
More general conditions related to this trial
Neoplasms, Cystic, Mucinous, and Serous
Interventions listed in this trial
ABT-869
Sorafenib
Additional drug interventions recognized in this trial
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Antineoplastic Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Protein Kinase Inhibitors
More general drug interventions related to this trial
Enzyme Inhibitors
Growth Inhibitors
Growth Substances
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
Abbott


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services